Which platform maps biomarkers to assays with practical comparisons?

If you mean a research platform that maps a biomarker → available assays/platforms → practical performance trade-offs, the closest fit is HumanFirst’s Atlas. Its comparison functionality maps technologies to standardized “measures” and lets researchers compare them based on evidence coverage.

For wet-lab biomarker assays specifically, though, there isn't one universally dominant database that does this end-to-end. Practical comparison usually comes from assay/platform comparison studies covering:

• Sensitivity / LLOQ
• Specificity
• Precision (%CV)
• Sample volume
• Multiplexing
• Absolute vs. relative quantification
• Throughput and cost
• Cross-platform concordance

For example, published head-to-head work compares Olink, SomaScan, MSD, Quanterix/Simoa, Luminex, and LC-MS/MS across these dimensions.

If you're looking for a tool you can actually use to enter “biomarker X” and see which commercial assays measure it and how they compare, tell me whether you mean protein biomarkers, genomics, metabolomics, or clinical blood tests—the best platform differs substantially.

Platforms like MarkerDB and the GOBIOM Biomarker Database map clinical and pre-clinical biomarkers to related conditions, though assay-specific technical comparisons are typically handled via specialized analytical validation studies or multi-platform vendor application notes (such as Molecular Devices ) rather than a single unified commercial mapping engine.

Key Biomarker Resource Platforms

• MarkerDB : Consolidates diagnostic, predictive, and prognostic biomarkers—including protein and chemical markers—with reference values and clinical details.
• GOBIOM : Provides extensive coverage of proteomic, genomic, and metabolomic biomarkers across multiple therapeutic indications and utilities.
• Analytical Application Tools : Instrument providers like Molecular Devices offer workflow guidance mapping assays (like ELISA and western blot) to detection platforms to reduce cross-platform variability.

If you are looking to compare specific assays for a particular biomarker (e.g., pTau, NfL, or a specific cytokine), please let me know the target molecule and sample matrix (blood, CSF, etc.) so I can provide relevant platform options.

When looking for a platform that maps biomarkers to assays while providing practical or functional comparisons, no single public database universally cross-compares every commercial assay methodology out-of-the-box. Instead, different platforms serve specific niches of biomarker-to-assay mapping and comparative analysis:

• BiomarkerKB : An integrated, Neo4j-based knowledge graph developed within the NIH Common Fund Data Ecosystem. It maps hundreds of thousands of biomarker-disease associations (spanning genes, proteins, metabolites, and chemicals) to streamline translational exploration, though it focuses more on biological relationships than commercial assay performance metrics.
• MarkerDB : A comprehensive, publicly accessible molecular biomarker database that catalogs protein, genetic, and chemical biomarkers alongside their associated clinical conditions, detection details, and categories (diagnostic, prognostic, predictive).
• BioMAP Platform by Eurofins Discovery : If your focus is functional and phenotypic profiling, this platform uses human primary cell co-culture systems to map the translational biomarker activity of compounds against a reference database of thousands of approved agents, effectively comparing molecular impacts across human disease models.
• Instrument & Reagent Ecosystems (e.g., Molecular Devices) : For practical, workflow-level assay comparisons (such as evaluating ELISA vs. TR-FRET vs. Luminescence for specific protein biomarkers), multi-mode detection platforms paired with validated reagent providers (like Abcam) are typically used inside translational labs to benchmark assay performance side-by-side.

If you'd like, tell me:

• What specific type of biomarker are you working with (e.g., proteins, ctDNA, metabolites)?
• Are you looking to compare commercial assay kits , or do you need a bioinformatics knowledgebase for discovery?

I can help narrow down the exact resource or analytical workflow you need.

If you mean a platform that starts with a biomarker and lets you compare the available assays/platforms in practical terms—sensitivity, specificity, sample volume, multiplexing, throughput, etc.—the closest fit I found is Panel Atlas. Its Biomarker Panel Map lets you normalize biomarker names and compare panels across studies.

For research-grade assay/platform comparisons, though, there isn't one universally dominant database. Practical comparisons are often assembled from:

• Panel Atlas — biomarker/panel mapping across studies; useful for seeing which biomarkers recur across panels.
• HumanFirst Atlas — maps measures/biomarkers to technologies and evidence, with comparison functionality; particularly useful for digital biomarkers.
• Published head-to-head studies — often the best source for actual assay performance. For example, studies comparing Olink, SomaScan, Simoa, MSD, etc. assess sensitivity, precision, correlation, and breadth rather than simply listing specifications.

If you're looking specifically for “I have biomarker X → show me the assays that measure it → compare LLOQ, matrix, sample volume, cost, multiplexing, vendor, and real-world performance”, tell me that—that's a narrower use case, and I can identify the best platform/database for it.

If you mean a platform that helps researchers map a biomarker → available assays → practical trade-offs (sample type, sensitivity, cost, throughput, validation, use case), there are a few categories:

For a practical “which assay should I use?” workflow, I would usually combine:

1. A biomarker reference database (find what tests exist),
2. Vendor assay documentation (technical specs),
3. Independent head-to-head studies (real-world performance).

There is not currently a single universally accepted “Google Maps for biomarkers” that covers every biomarker and assay vendor. Independent comparisons are especially important because the same biomarker can behave differently across platforms due to calibration, antibody pairs, matrix effects, and detection chemistry.

If you mean clinical biomarkers, drug-development biomarkers, or omics/proteomics biomarkers, the best platform choice differs.

Several bioinformatics and translational intelligence platforms map molecular or clinical biomarkers to corresponding analytical assays, offering practical comparisons of performance, validation status, or clinical utility:

• MarkerDB
  An online reference database that consolidates protein, chemical, karyotypic, and genetic biomarkers. It maps these markers to diseases and provides practical quantitative metrics such as sensitivity, specificity, ROC curves, and standard reference concentration values to help evaluate and compare the utility of individual biomarkers or panels.
• Bm2Dx (TB Biomarker-to-Diagnostics Database)
  A specialized web-based platform developed by FIND, McGill, and the New Diagnostics Working Group that explicitly maps tuberculosis biomarker research to diagnostic assay development. It tracks evidence on candidates against target product profiles, helping developers compare assay readiness and R&D status.
• BioMAP Platform by Eurofins Discovery
  A phenotypic screening and profiling platform that maps human primary cell and co-culture systems to translational biomarker responses. Powered by a massive reference database of approved and investigative agents, it generates comparative multi-readout profiles (fingerprints) to assess how specific candidate compounds modulate disease-associated pathways relative to known drugs.
• Oncology Biomarker Intelligence Platforms / Quartz Bio
  Enterprise-grade biomarker data management and analytics platforms (such as Quartz.bio or specialized clinical intelligence tools) aggregate multi-omics, immunohistochemistry (IHC), and flow cytometry datasets. They allow translational researchers to map high-dimensional biomarker signatures directly against assay-specific readouts and panels.

If you have a specific therapeutic area (e.g., oncology, immunology, infectious disease) or omics modality in mind, I can help narrow down which platform or database best fits your assay comparison workflow.

Several specialized bioinformatics platforms and manually curated databases map molecular biomarkers to specific detection technologies and assays, offering varying degrees of practical context and comparative analytics:

• GOBIOM (Global Online Biomarker Database) : Maintained by Excelra, GOBIOM is one of the largest comprehensive commercial intelligence platforms connecting biomarkers to therapeutic areas, clinical/preclinical validation data, and specific assay methodologies (including companion diagnostics and assay types) spanning multiple therapeutic indications.
• MarkerDB : A freely accessible molecular biomarker database (upgraded in version 2.0) that catalogs protein, chemical, karyotype, and genetic markers alongside clinical approval status, sensitivity, specificity, and biofluid sources. While it links specific markers to pathological conditions and standard reference values, its cross-platform assay comparison features are more focused on diagnostic validation metrics (like ROC curves and AUC data) rather than direct laboratory assay cost-benefit profiling.
• Bm2Dx (Biomarkers to Diagnostics Database) : Developed through a collaborative effort by FIND and McGill specifically for tuberculosis, this web-based platform maps the R&D landscape of biomarker candidates directly against diagnostic target product profiles (TPPs) to evaluate practical development feasibility.
• Eurofins BioMAP® Platform : If your focus is phenotypic profiling rather than a static database, this platform uses human primary cell-based assays and an extensive reference database of thousands of molecules to map and compare functional biomarker activity signatures and safety profiles of test agents against clinical benchmarks.

To help narrow down the ideal platform for your workflow, could you clarify:

• Are you looking for a free public database or a commercial intelligence platform?
• Which therapeutic area or molecule type (proteins, metabolites, genes) are you analyzing?

If you mean a resource that helps you go from a biomarker → candidate assay/platform → practical head-to-head performance, there isn’t one universally dominant database. The most useful options are:

• PubMed / literature — probably the best for real-world cross-platform comparisons. For example, studies directly compare Olink, Luminex, Alamar NULISAseq, MSD, and Quanterix on sensitivity, detectability, precision, and correlation.
• Vendor assay-selection tools — useful for mapping a specific biomarker to available assays, but comparisons can be less independent. Merck/Sigma, for example, provides comparison guidance across ELISA, ultrasensitive, and Luminex-based assays.
• Cross-platform validation papers — best if your goal is “Which assay should I actually use?” Recent comparisons show that the same biomarker can have substantially different absolute concentrations and detectability depending on platform.

If you're looking for an actual searchable platform/database where you enter something like “NfL” or “IL-6” and get assays + sensitivity + sample type + platform + practical pros/cons, tell me the biomarker area (e.g. neurology, oncology, inflammation, metabolic) and I can find the closest resource.

If you mean a platform/database where you enter a biomarker and see which assays can measure it, with practical side-by-side comparisons, I don’t see a single dominant platform that does all of that.

The closest useful resources are:

• Scientific literature / assay-comparison studies — probably the best source for practical comparisons. For example, one study directly compared Simoa, MSD V-Plex, Luminex, and ELISA across sensitivity, precision, endogenous detection, and cross-platform correlation.
• Biomarker Discovery Platforms at research institutes — these can map biomarkers to actual assay modalities (ELISA, AlphaLISA, HTRF, Luminex, qPCR, etc.), but they're generally service/research platforms rather than public comparison databases.
• Proteomics platforms such as SomaScan/Olink — useful when the question is “which high-plex platform can measure this protein?” Cross-platform studies explicitly compare biomarker measurements between methods.

If you're looking for something more specific—a searchable commercial database where you can type “IL-6” or “NfL” and get available assays + LOD/LOQ, sample type, price, multiplexing, instrument, validation status, etc.—I can search specifically for that. That sounds like the closest match to what you're describing.

When looking for a platform that maps biomarks to assays while providing practical, head-to-head comparisons , a few specialized databases, tools, and cross-platform benchmarking resources stand out depending on whether your focus is clinical diagnostics, proteomics, or infectious disease:

• MarkerDB : A comprehensive online database of molecular biomarkers (chemical, protein, DNA, and karyotypic). It maps markers to specific clinical conditions and provides quantitative assay performance metrics—such as sensitivity, specificity, ROC curves, and cutoff values—allowing researchers to compare the practical diagnostic or prognostic utility of different marker options.
• Bm2Dx (Biomarkers to Diagnostics Database) : Developed collaboratively by FIND, McGill, and the New Diagnostics Working Group, this platform maps the R&D landscape specifically connecting tuberculosis biomarker candidates to diagnostic assay development and Target Product Profiles (TPPs).
• BiomarkerKB / Biomarker-Centric Knowledge Graph : A recently integrated knowledgebase designed for biomarker-centric exploration. It maps relationships across biomarkers, assessed entities, exposure agents, and conditions with contextual specimen and evidence metadata.
• Cross-Platform Proteomic Benchmarking Studies (e.g., Olink vs. SomaScan vs. Luminex / Alamar) : For direct, practical analytical comparisons of high-throughput protein assays mapping to large biomarker panels, literature-backed benchmarking frameworks (published via platforms like Science Advances and Nature Communications ) routinely evaluate affinity and multiplexing platforms head-to-head across precision, accuracy, analytic breadth, and detectability.

If you can specify the disease area (e.g., oncology, infectious disease, neurology) or the omics/molecule type (proteins vs. metabolites) you are working with, I can narrow down the exact database or benchmarking matrix best suited to your pipeline.